Sexually Transmitted Diseases Diagnostics - Market Insights, Competitive Landscape, and Market Forecast - 2030

Sexually transmitted diseases (std) diagnostics by type of disease (chlamydia, gonorrhea & syphilis, herpes simplex virus, human papilloma virus, human immunodeficiency virus, and others), by testing (laboratory devices [pcr, lteral flow readers immunochromatographic assay, flow cytometers, absorbance microplate readers enzyme linked immunosorbent assay, and others] and point of care devices [phone chips, portable/bench, and diagnostic kits]), by diagnostic test (cultural/isolated of organisms, molecular test, immunology assay, and others), by end-user (hospitals, diagnostic centers, and others), and by geography is expected to advance at a respectable CAGR forecast till 2027 owing to the increasing demand for non-invasive cosmetic and hair removal procedures and rise in spending on by young and adult people on personal care.

The global sexually transmitted diseases (STD) diagnostics market is estimated to grow at a CAGR of 7.81% during the forecast period from 2022 to 2027. The sexually transmitted diseases (STD) diagnostics market is observing a remarkable market growth due to the factors such as the growing incidence and prevalence of sexually transmitted diseases, rising innovations in the development of STD diagnostics devices, rise in implementation of national screening programs by various government organizations, surging demand of rapid point of care testing over the traditional testing, increasing product launches and approvals, presence of key players in the market, and other factors will create a requisite for the sexually transmitted diseases diagnostics devices in the market. Therefore, the market for sexually transmitted diseases (STD) diagnostics is estimated to grow at a substantial CAGR during the forecast period from 2022 to 2027.

SEXUALLY TRANSMITTED DISEASES (STD) DIAGNOSTICS MARKET DYNAMICS:

One of the key aspect for driving the sexually transmitted diseases (STD) diagnostics market is the rising prevalence and incidence of various STD such as syphilis, gonorrhea, chlamydia, hepatitis B, herpes simplex virus (HSV), HIV and human papillomavirus (HPV).

For instance, as per the data provided by the World Health Organization (WHO) 2022, it was estimated that more than 1 million sexually transmitted infections (STIs) are acquired every day worldwide, the majority of which are asymptomatic. Also, every year there are an estimated 374 million new infections which can be curable. Additionally, the source also stated that more than 500 million people 15-49 years are estimated to have a genital infection with herpes simplex virus, every year. Further, human papillomavirus (HPV) infection is associated with over 311, 000 cervical cancer deaths each year. Thus, the number of STD cases is high across the globe, which will ultimately lead to the increased demand of the diagnostic devices in the market, thereby propelling the overall market growth of the STD diagnosis in the upcoming years.

Furthermore, HIV continues to be a major public health issue, globally. The government emphases on proper screening of the HIV/AIDS that an early treatment or intervention can be provided and can ultimately reduce the incidence and mortality rate among the population. For instance, in March 2022, National Chlamydia Screening Program (NCSP) was organized in the United Kingdom. The main aim of the program is to reduce the risk of untreated chlamydia infection. This program also focused on reducing the time to test results and treatment and re-testing after treatment. The program is also changing from prevention and control to focusing on reducing the harms from untreated chlamydia infection by primarily screening women and girls.

Additionally, in 2022, the Centers for Disease Control and Prevention (CDC) recommended and issued guidelines for screening of sexually transmitted diseases in order to create awareness towards screening programs for STDs and increasing burden of STDs across the globe. It has issued separate STD screening guidelines for every group of the population such as women, pregnant women, men who have sex with women, men who have sex with men, transgender and gender diverse persons, and persons with HIV. Thus, the increase in the number of screening programs across the globe is expected to increase the number of cases of STD, which in turn is anticipated to increase the demand for STD diagnostic products. Henceforth, substantial market growth is anticipated over the forecast period of 2022 - 2027.

Therefore, the factors stated above collectively will drive the overall sexually transmitted diseases (STD) diagnostics market during the forecast period from 2022-2027.

However, the stringent regulatory approvals of the diagnostic devices, social stigma associated with patients visiting physicians for STD diagnosis and treatment, and others may prove to be challenging factors for sexually transmitted diseases (STD) diagnostics market growth.

The sexually transmitted diseases (STD) diagnostics market was negatively impacted during the period of COVID- 19 pandemic. In order to curb the spread of infection the government across the globe imposed strict lockdown rules, resulting in the shortage of supply chains, raw materials, and other resources in the market, leading to the decreased manufacturing of all the medical devices. Moreover, the patients and physicians postponed many elective surgeries, diagnostic tests, laboratory visits, and other healthcare facilities in order to stop the spread of the infection, thereby decreasing the number of in-patient visits in hospitals and clinics for diagnosis and treatment. However, vaccine development of COVID-19 has initiated the process of economic recovery with the easing of lockdown restrictions and the return of normalcy in the economic landscape, which has initiated the process of resumption of regular healthcare services such as regular out-patients visits for treatments and diagnosis in hospitals, clinics, and laboratories, thereby bringing the demand for products on track in the sexually transmitted diseases (STD) diagnostic devices market.

SEXUALLY TRANSMITTED DISEASES (STD) DIAGNOSTICS MARKET SEGMENT ANALYSIS:

Sexually Transmitted Diseases (STD) Diagnostics Market by Type of Disease (Chlamydia, Gonorrhea & Syphilis, Herpes Simplex Virus, Human Papilloma Virus, Human Immunodeficiency Virus, and Others), Testing (Laboratory Devices [PCR, Lteral Flow Readers Immunochromatographic Assay, Flow Cytometers, Absorbance Microplate Readers Enzyme Linked Immunosorbent Assay, and Others] and Point Of Care Devices [Phone Chips, Portable/Bench, and Diagnostic Kits]), Diagnostic Test (Cultural/Isolated Of Organisms, Molecular Test, Immunology Assay, and Others), End-User (Hospitals, Diagnostic Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the testing segment of the sexually transmitted diseases (STD) diagnostics market, the PCR segment is expected to have a significant revenue share in the year 2021. This was primarily owing to the rising availability of technological advanced products in the market, rising product launches and approvals in the market, and reliability and high accuracy provided by the segment.

More the PCR testing detect the small amounts of DNA in a sample in order to detect the STD in a patient. Also, PCR techniques can sometimes detect sexually transmitted infections and other diseases earlier than other tests
Additionally, presence of advanced products in the market will likely propel the demand of PCR diagnostic testing in the market. For instance, Abbott laboratories offer an in vitro reverse transcription-polymerase chain reaction (RT-PCR) assay and in vitro polymerase chain reaction (PCR) assay for detection of various sexually transmitted diseases such as gonorrhea and others caused by Chlamydia trachomatis, Trichomonas vaginalis, and Mycoplasma genitalium. Similarly, Qiagen Inc. offers a wide range of diagnostics test kits, including STI tests for detection of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) infections with high clinical sensitivity and specificity that are used to detect various sexually transmitted diseases.

Moreover, increasing product launches and regulatory approvals across the globe will bolster the demand of the segment. For instance, in May 2022, Qiagen Inc. launched NeuMoDxHSV 1/2 Quant Assay for the quantification and differentiation of herpes simplex virus type 1 (HSV-1) DNA and/or herpes simplex virus type 2 (HSV-2) with approval from the European Commission. The emergence of this assay is allowing the company to expand its product portfolio in laboratory testing which ultimately helps the market growth owing to the innovative tests.

Additionally, in November 2021, Roche launched Cobas 5800 System, a real-time PCR molecular testing solution, a new molecular laboratory instrument, in countries accepting the CE mark. This launch is helping the company in broadening its diagnostics product range for various applications including STD diagnostics which is expected to contribute to the growth of the market studied.

Therefore, owing to the above-mentioned factors, the demand of the PCR testing rises, thereby the category is expected to witness a considerable growth eventually contributing to the overall growth of the global sexually transmitted diseases (STD) diagnostics market during the forecast period.

NORTH AMERICA IS EXPECTED TO DOMINATE THE OVERALL SEXUALLY TRANSMITTED DISEASES (STD) DIAGNOSTICS MARKET:

Among all the regions, North America is expected to dominate the global sexually transmitted diseases (STD) diagnostics in the year 2021 and is expected to do the same during the forecast period from 2022-2027.

This can be ascribed to increasing prevalence and incidence of STD in the region, rise in implementation of national screening programs by various government organizations, the presence of key market players, and among the other key factors that contribute to the growth of the sexually transmitted diseases (STD) diagnostics market in the North America.

For instance, as per the Public Health Agency of Canada 2019, in 2019, a total of 139,386 cases of chlamydia were reported, for a rate of 370.8 cases per 100,000 population, in Canada. Also, as per the same source, in 2019, in Canada, a total of 35,443 cases of gonorrhea were reported.

Additionally, according to the CDC 2021, it was estimated that about 20 percent of the U.S. population, approximately one in five people in the United States had an STI on any given day in 2018.

Furthermore, as per the CDC 2020, Chlamydia trachomatis infection was the most prevalent notifiable sexually transmitted infection in the United States in 2020 with a total of 1,579,885 cases. Also, as per the above mentioned source at the end of 2019, the number of Americans living with HIV was nearly 1,189,700.

The increasing awareness among the people about the early diagnosis of STD by the government agencies will increase the demand of STD diagnosis in the upcoming years. For instance, in August 2020, the United States Department of Health and Human Services developed a Sexually Transmitted Infections National Strategic Plan (STI Plan). Five high-level goals that frame the STI Plan's more precise targets are presented beside this vision. The prevention of new STIs is one of the five aims and related objectives. In communities and populations most affected by STIs, increase access to high-quality, inexpensive STI secondary prevention, including screening, care, and treatment. To identify and treat STIs, including novel and emerging disease threats, support the development and adoption of innovative STI diagnostic tools, therapeutic agents, and other interventions. Thus, it is anticipated that such measures will accelerate market expansion.

Furthermore, the presence of key players in the region, advancement and adoption of new technologies played a vital role in increasing growth for the STD self-diagnostics in the region.

Therefore, the interplay of the aforementioned factors above would provide a conducive growth environment for the North American region in the sexually transmitted disease (STD) diagnosis market. 

SEXUALLY TRANSMITTED DISEASES (STD) DIAGNOSTICS MARKET KEY PLAYERS:

Some of the key market players operating in the sexually transmitted diseases (STD) diagnostics market includes Abbott, DiaSorin S.p.A., Hologic, Inc., Siemens Healthcare GmbH, Cephied (Danaher Corporation), MedMira Inc., QIAGEN, F. Hoffmann-La Roche Ltd, bioMérieux SA, Bio-Rad Laboratories, Inc., BD., Thermo Fisher Corporation, Quidel Corporation., Grifols, S.A., Orasure technologies Inc., and others.

RECENT DEVELOPMENTAL ACTIVITIES IN SEXUALLY TRANSMITTED DISEASES (STD) DIAGNOSTICS MARKET:

• In May 2022, BD, a leading global medical technology company, announced the United States launch of its new, fully automated, high-throughput infectious disease molecular diagnostics platform. It is the first test available on the new system is the BD CTGCTV2 molecular assay, a single test that detects the three most prevalent non-viral sexually transmitted infections (STIs) - Chlamydia trachomatis (CT), Neisseria gonorrhoeae (GC) and Trichomonas vaginalis (TV).
• In May 2022, The Food and Drug Administration approved Abbott's Alinity m STI Assay which detects and differentiates four common sexually transmitted infections (STIs).
• In May 2022, Medmira Inc. received CE mark for its Multiplo Complete Syphilis (TP/nTP) Antibody Test (Multiplo TP/nTP). This approval enables the company to further strengthen its product offering in all markets accepting the CE mark.
• In April 2019 Quest Diagnostics, the world's leading provider of diagnostic information services, launched three new sexually transmitted disease (STD) laboratory test packages that individuals can purchase online for some of the most prevalent STDs in the United States.

KEY TAKEAWAYS FROM THE SEXUALLY TRANSMITTED DISEASES (STD) DIAGNOSTICS MARKET REPORT STUDY

• Market size analysis for current sexually transmitted diseases (STD) diagnostics market size (2020), and market forecast for 5 years (2021-2027)
• The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the sexually transmitted diseases (STD) diagnostics market.
• Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years
• Key companies dominating the global sexually transmitted diseases (STD) diagnostics market.
• Various opportunities available for the other competitor in the sexually transmitted diseases (STD) diagnostics market space.
• What are the top performing segments in 2020? How these segments will perform in 2027.
• Which is the top-performing regions and countries in the current sexually transmitted diseases (STD) diagnostics market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for sexually transmitted diseases (STD) diagnostics market growth in the coming future?

TARGET AUDIENCE WHO CAN BE BENEFITED FROM THIS SEXUALLY TRANSMITTED DISEASES (STD) DIAGNOSTICS MARKET REPORT STUDY

• Sexually transmitted diseases (STD) diagnostics products providers
• Research organizations and consulting companies
• Sexually transmitted diseases (STD) diagnostics -related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and Traders dealing in sexually transmitted diseases (STD) diagnostics
• Various end users who want to know more about the sexually transmitted diseases (STD) diagnostics market and latest technological developments in the sexually transmitted diseases (STD) diagnostics market.

FREQUENTLY ASKED QUESTIONS FOR SEXUALLY TRANSMITTED DISEASES (STD) DIAGNOSTICS MARKET:

1. What is sexually transmitted diseases (STD) diagnostics?

The Sexually Transmitted Diseases (STD) Diagnostics are used to permanently or temporarily remove hair from the head, face, or body.

2. What is the global market for sexually transmitted diseases (STD) diagnostics?

The global sexually transmitted diseases (STD) diagnostics market is estimated to grow at a CAGR of 7.81% during the forecast period from 2022 to 2027.

3. What are the drivers for global sexually transmitted diseases (STD) diagnostics market?

The sexually transmitted diseases (STD) diagnostics market is witnessing a positive market growth owing to the factors such as the growing incidence and prevalence of sexually transmitted diseases, rising innovations in the development of STD diagnostics devices, rise in implementation of national screening programs by various government organizations, surging demand of rapid point of care testing over the traditional testing, increasing product launches and approvals, presence of key players in the market, and others will create an exigency for the sexually transmitted diseases (STD) diagnostics market.

4. Who are the key players operating in the global sexually transmitted diseases (STD) diagnostics market?

Some of the key market players operating in the sexually transmitted diseases (STD) diagnostics market includes Abbott, DiaSorin S.p.A., Hologic, Inc., Siemens Healthcare GmbH, Cephied (Danaher Corporation), MedMira Inc., QIAGEN, F. Hoffmann-La Roche Ltd, bioMérieux SA, Bio-Rad Laboratories, Inc., BD., Thermo Fisher Corporation, Quidel Corporation., Grifols, S.A., Orasure technologies Inc., and others.

5. Which region has the highest share in sexually transmitted diseases (STD) diagnostics market?

Among all the regions, North America is estimated to amass the significant revenue share in the global sexually transmitted diseases (STD) diagnostics market. This can be ascribed to the increasing prevalence and incidence of STD in the region, rise in implementation of national screening programs by various government organizations, and the presence of key market players in the region are the reasons which acts as a supportive factor for the North America sexually transmitted diseases (STD) diagnostics market growth.


This product will be delivered within 2 business days.